Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) had its target price increased by TD Securities to C$26.00 in a research note issued on Wednesday, reports. The firm presently has a “hold” rating on the specialty pharmaceutical company’s stock. TD Securities’ price target suggests a potential upside of 21.21% from the stock’s current price.

Several other equities research analysts also recently commented on VRX. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Valeant Pharmaceuticals Intl in a report on Thursday, June 29th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a C$25.00 target price on shares of Valeant Pharmaceuticals Intl in a report on Monday, June 19th. Finally, Scotiabank upped their target price on Valeant Pharmaceuticals Intl to C$19.00 and gave the company a “sector perform” rating in a report on Wednesday, May 10th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of C$23.33.

Valeant Pharmaceuticals Intl (TSE VRX) traded up 0.89% on Wednesday, hitting $21.64. The stock had a trading volume of 564,390 shares. The stock has a 50-day moving average of $18.18 and a 200-day moving average of $17.31. The company’s market cap is $7.53 billion. Valeant Pharmaceuticals Intl has a one year low of $11.20 and a one year high of $42.25.

WARNING: “Valeant Pharmaceuticals Intl Inc (TSE:VRX) PT Raised to C$26.00” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at

In other Valeant Pharmaceuticals Intl news, Director Schutter Richard Urbain De acquired 20,000 shares of Valeant Pharmaceuticals Intl stock in a transaction that occurred on Thursday, May 11th. The stock was purchased at an average cost of C$13.90 per share, with a total value of C$278,000.00.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Stock Target Prices

Analyst Recommendations for Valeant Pharmaceuticals Intl (TSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with's FREE daily email newsletter.